BR112018005164A2 - anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer - Google Patents
anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncerInfo
- Publication number
- BR112018005164A2 BR112018005164A2 BR112018005164A BR112018005164A BR112018005164A2 BR 112018005164 A2 BR112018005164 A2 BR 112018005164A2 BR 112018005164 A BR112018005164 A BR 112018005164A BR 112018005164 A BR112018005164 A BR 112018005164A BR 112018005164 A2 BR112018005164 A2 BR 112018005164A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- antibodies
- cancer
- treating
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
a presente invenção refere-se a anticorpos anti-pd1 e métodos de uso dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15188061 | 2015-10-02 | ||
PCT/EP2016/073248 WO2017055443A1 (en) | 2015-10-02 | 2016-09-29 | Anti-pd1 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018005164A2 true BR112018005164A2 (pt) | 2019-10-01 |
Family
ID=54252164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018005164A BR112018005164A2 (pt) | 2015-10-02 | 2016-09-29 | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer |
Country Status (33)
Country | Link |
---|---|
US (4) | US20170247454A1 (pt) |
EP (1) | EP3356404B1 (pt) |
JP (1) | JP6654694B2 (pt) |
KR (1) | KR102072317B1 (pt) |
CN (1) | CN108368173B (pt) |
AR (1) | AR106232A1 (pt) |
AU (1) | AU2016329251B2 (pt) |
BR (1) | BR112018005164A2 (pt) |
CA (1) | CA2997799A1 (pt) |
CL (1) | CL2018000595A1 (pt) |
CO (1) | CO2018003477A2 (pt) |
CR (1) | CR20180151A (pt) |
DK (1) | DK3356404T3 (pt) |
ES (1) | ES2895034T3 (pt) |
HK (1) | HK1259019A1 (pt) |
HR (1) | HRP20211594T1 (pt) |
HU (1) | HUE056033T2 (pt) |
IL (1) | IL257858B (pt) |
LT (1) | LT3356404T (pt) |
MA (1) | MA43018B1 (pt) |
MX (1) | MX2018003629A (pt) |
MY (1) | MY190297A (pt) |
NZ (1) | NZ741129A (pt) |
PE (1) | PE20181092A1 (pt) |
PH (1) | PH12018500711A1 (pt) |
PL (1) | PL3356404T3 (pt) |
PT (1) | PT3356404T (pt) |
RS (1) | RS62450B1 (pt) |
RU (1) | RU2746409C1 (pt) |
SI (1) | SI3356404T1 (pt) |
TW (1) | TWI625336B (pt) |
UA (1) | UA123826C2 (pt) |
WO (1) | WO2017055443A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
EP3277320A4 (en) | 2015-03-30 | 2018-08-01 | Stcube, Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
WO2017040790A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
LT3356411T (lt) | 2015-10-02 | 2021-09-10 | F. Hoffmann-La Roche Ag | Bispecifiniai antikūnai, specifiniai pd1 ir tim3 |
CN108473584B (zh) | 2015-11-03 | 2022-01-14 | 詹森生物科技公司 | 特异性结合pd-1和tim-3的抗体及其用途 |
TWI754621B (zh) | 2015-11-18 | 2022-02-11 | 美商默沙東藥廠 | Pd1及/或 lag3結合劑 |
KR20180085793A (ko) * | 2015-12-02 | 2018-07-27 | 주식회사 에스티큐브 | 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법 |
PL3400246T3 (pl) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3 |
CN109195991B (zh) | 2016-03-29 | 2023-10-31 | 斯特库比股份有限公司 | 对糖基化pd-l1特异的双重功能抗体及其使用方法 |
DK3476865T3 (da) | 2016-06-28 | 2023-12-18 | Biocytogen Pharmaceuticals Beijing Co Ltd | Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf |
KR20190031299A (ko) | 2016-07-20 | 2019-03-25 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법 |
CA3037144A1 (en) | 2016-09-16 | 2018-03-22 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
CN109952317A (zh) | 2016-09-19 | 2019-06-28 | 细胞基因公司 | 使用pd-1结合蛋白治疗免疫病症的方法 |
JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Pd−1結合タンパク質を使用して白斑を治療する方法 |
CN110392692B (zh) | 2017-04-03 | 2023-07-21 | 豪夫迈·罗氏有限公司 | 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物 |
KR102408873B1 (ko) * | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
US11492403B2 (en) | 2017-04-20 | 2022-11-08 | Dana-Farber Cancer Institute, Inc. | Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof |
KR102414120B1 (ko) | 2017-08-03 | 2022-06-28 | 암젠 인크 | 인터류킨-21 뮤테인 및 치료 방법 |
WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
WO2019094265A1 (en) * | 2017-11-10 | 2019-05-16 | Armo Biosciences, Inc. | Pd1 polypeptide binding molecules |
PE20211270A1 (es) | 2018-01-12 | 2021-07-19 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento |
EP3746480A1 (en) | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
EP3755716A4 (en) | 2018-02-23 | 2021-08-04 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-PD-1 ANTIBODIES AND THEIR USES |
TWI708787B (zh) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
WO2020021061A1 (en) * | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
CN113227142B (zh) | 2018-11-19 | 2022-11-29 | 百奥赛图(北京)医药科技股份有限公司 | 抗pd-1抗体及其用途 |
CN114630675A (zh) | 2019-06-18 | 2022-06-14 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合 |
EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Pd−1/cd3二重特異性タンパク質による血液がん治療 |
WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
WO2021209402A2 (en) | 2020-04-15 | 2021-10-21 | F. Hoffmann-La Roche Ag | Immunoconjugates |
JP2023524257A (ja) | 2020-05-05 | 2023-06-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1軸阻害剤に対する応答の予測 |
WO2022189380A1 (en) | 2021-03-09 | 2022-09-15 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
US20240092856A1 (en) | 2021-03-09 | 2024-03-21 | Hoffmann-La Roche Inc. | Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
WO2023062050A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
DE122004000036I1 (de) | 1992-11-13 | 2005-07-07 | Biogen Idec Inc | Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma. |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1763097B (zh) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
PT1222292E (pt) | 1999-10-04 | 2005-11-30 | Medicago Inc | Metodo para regulacao da transcricao de genes exogenos na presenca de azoto |
JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
NZ518764A (en) | 1999-12-29 | 2004-02-27 | Immunogen Inc | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
BR0110610A (pt) | 2000-04-11 | 2003-04-29 | Genentech Inc | Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP1916303B1 (en) | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B8 (pt) | 2002-12-16 | 2023-02-28 | Genentech Inc | Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida |
BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
US7527791B2 (en) | 2004-03-31 | 2009-05-05 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES |
LT2397156T (lt) | 2005-06-08 | 2017-02-27 | Dana-Farber Cancer Institute, Inc. | Būdai ir kompozicijos, skirti nuolatinių infekcijų ir vėžio gydymui inhibuojant užprogramuotos ląstelės mirties-1 (pd-1) kelią |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
NZ619576A (en) | 2006-12-27 | 2014-07-25 | Harvard College | Compositions and methods for the treatment of infections and tumors |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
KR20100054780A (ko) | 2007-06-18 | 2010-05-25 | 엔.브이.오가논 | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
EP2195347A1 (en) | 2007-08-17 | 2010-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating and diagnosing hematologic malignancies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドIsis Innovationlimited | Pd−1特異抗体およびその使用 |
CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
EP3530672A1 (en) * | 2008-09-26 | 2019-08-28 | Dana Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PL2417156T3 (pl) | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trójwartościowe, bispecyficzne przeciwciała |
EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
US8993731B2 (en) * | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
HUE041335T2 (hu) * | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
EP2699264B1 (en) * | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
SI2748202T1 (sl) | 2011-08-23 | 2018-10-30 | Roche Glycart Ag | Bispecifične molekule, ki se vežejo na antigen |
JP6060162B2 (ja) | 2011-08-23 | 2017-01-11 | ロシュ グリクアート アーゲー | 2つのFabフラグメントを含むFc不含抗体および使用方法 |
WO2013164325A1 (en) | 2012-05-02 | 2013-11-07 | F. Hoffmann-La Roche Ag | Multispecific antigen binding proteins |
RU2014149681A (ru) | 2012-05-24 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Антитела с множественной специфичностью |
LT2872534T (lt) * | 2012-07-13 | 2018-10-25 | Roche Glycart Ag | Dvigubai specifiniai anti-vegf/anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
JP6133444B2 (ja) | 2013-02-26 | 2017-05-24 | ロシュ グリクアート アーゲー | 二重特異性t細胞活性化抗原結合分子 |
TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US10239942B2 (en) * | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
-
2016
- 2016-09-29 AU AU2016329251A patent/AU2016329251B2/en active Active
- 2016-09-29 UA UAA201804633A patent/UA123826C2/uk unknown
- 2016-09-29 CA CA2997799A patent/CA2997799A1/en active Pending
- 2016-09-29 BR BR112018005164A patent/BR112018005164A2/pt active Search and Examination
- 2016-09-29 CN CN201680055439.1A patent/CN108368173B/zh active Active
- 2016-09-29 PT PT167744994T patent/PT3356404T/pt unknown
- 2016-09-29 LT LTEPPCT/EP2016/073248T patent/LT3356404T/lt unknown
- 2016-09-29 DK DK16774499.4T patent/DK3356404T3/da active
- 2016-09-29 JP JP2018516670A patent/JP6654694B2/ja active Active
- 2016-09-29 SI SI201631371T patent/SI3356404T1/sl unknown
- 2016-09-29 KR KR1020187012254A patent/KR102072317B1/ko active IP Right Grant
- 2016-09-29 HU HUE16774499A patent/HUE056033T2/hu unknown
- 2016-09-29 US US15/280,810 patent/US20170247454A1/en not_active Abandoned
- 2016-09-29 EP EP16774499.4A patent/EP3356404B1/en active Active
- 2016-09-29 RU RU2018115986A patent/RU2746409C1/ru active
- 2016-09-29 RS RS20211227A patent/RS62450B1/sr unknown
- 2016-09-29 NZ NZ741129A patent/NZ741129A/en unknown
- 2016-09-29 WO PCT/EP2016/073248 patent/WO2017055443A1/en active Application Filing
- 2016-09-29 ES ES16774499T patent/ES2895034T3/es active Active
- 2016-09-29 MX MX2018003629A patent/MX2018003629A/es unknown
- 2016-09-29 IL IL257858A patent/IL257858B/en unknown
- 2016-09-29 PE PE2018000405A patent/PE20181092A1/es unknown
- 2016-09-29 HR HRP20211594TT patent/HRP20211594T1/hr unknown
- 2016-09-29 MY MYPI2018701270A patent/MY190297A/en unknown
- 2016-09-29 MA MA43018A patent/MA43018B1/fr unknown
- 2016-09-29 CR CR20180151A patent/CR20180151A/es unknown
- 2016-09-29 PL PL16774499T patent/PL3356404T3/pl unknown
- 2016-09-30 TW TW105131771A patent/TWI625336B/zh active
- 2016-09-30 AR ARP160103011A patent/AR106232A1/es unknown
-
2018
- 2018-03-07 CL CL2018000595A patent/CL2018000595A1/es unknown
- 2018-03-28 PH PH12018500711A patent/PH12018500711A1/en unknown
- 2018-03-28 CO CONC2018/0003477A patent/CO2018003477A2/es unknown
- 2018-12-18 US US16/224,553 patent/US20190382489A1/en not_active Abandoned
-
2019
- 2019-01-29 HK HK19101507.3A patent/HK1259019A1/zh unknown
-
2022
- 2022-06-30 US US17/810,242 patent/US20230143310A1/en not_active Abandoned
-
2023
- 2023-03-03 US US18/178,278 patent/US20230183349A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018005164A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
AR099465A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
BR112019004998A2 (pt) | anticorpos anti-pd-1(cd279) | |
BR112016020112A2 (pt) | anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica | |
BR112019002687A2 (pt) | receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos | |
BR112018006350A2 (pt) | anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo | |
BR112016010706A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo | |
BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
BR112018003186A2 (pt) | anticorpos anti-pd-1 e seus métodos de uso | |
BR112019003129A2 (pt) | composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer. | |
BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
BR112017011326A2 (pt) | anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune | |
AR090549A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
BR112015029009A2 (pt) | Anticorpos, ácido nucleico, célula hospedeira, método de produção de anticorpo, formulação farmacêutica e usos de um anticorpo | |
BR112016008146A2 (pt) | Anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos para detectar um câncer, de identificação e de seleção de um paciente com câncer | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CO2020003882A2 (es) | Anticuerpo multiespecifico | |
BR112015032718A2 (pt) | composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |